Compare Wendys Co (WEN) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Wendys Co vs State Street SPDR S&P Biotech ETF — how do they compare? Wendys Co trades at $6.2 (market cap $1.19B), while State Street SPDR S&P Biotech ETF trades at $154 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is far larger — about 8.5× Wendys Co's market cap, and Wendys Co pays a 4.49% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Wendys Co for 77 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| WEN | XBI | |
|---|---|---|
Market Cap | $1.19B | $10.11B |
Volume | 5,622,905 | 12,903,266 |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $9.33 | $169.55 |
52-Week Low | $6.10 | $104.99 |
Typical Hold Time | 77 Days | 38 Days |
Enterprise Value | $4.92B | — |
Dividend Yield | 4.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Wendy's (WEN) trades at $6.16, down 71% over five years, with a bearish technical signal and recent price near multi-year lows. The company faces declining same-store sales, a major franchisee bankruptcy (Meritage Hospitality, September 2026), and net income margin compression from 7.58% in 2025 to 5.72% in 2026. Valuation appears low with a P/E of 9.45 and P/S of 0.54, but high debt and operational challenges weigh on sentiment. Recent earnings beats provide some positive momentum, but competitive pressures persist.
The outlook remains cautious due to franchisee instability and sales declines. Investment opportunity lies in potential turnaround under new CEO Bob Wright and cheap valuation, but risks include further store closures, debt burden, and intense burger chain competition. Analyst consensus is mixed with a $7.58 price target, but 65% hold ratings reflect uncertainty.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Wendys Co
The Wendy's Company is the second-largest burger quick-service restaurant, or QSR, chain in the United States by systemwide sales, with $11.1 billion in 2021, narrowly edging Burger King ($10.3 billion) and clocking in well behind wide-moat McDonald's ($45.7 billion). After divestitures of Tim Hortons (2006) and Arby's (2011), the firm manages just the burger banner, generating sales across a footprint that spans almost 7,000 total units in 30 countries. Wendy's generates revenue from the sale of hamburgers, chicken sandwiches, salads, and fries throughout its company-owned footprint, through franchise royalty and marketing fund payments remitted by its franchisees, which account for 94% of stores, and through franchise flipping and advisory fees.
Read more on WEN →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
